No Data
Novo Nordisk Cuts Guidance as Copycat Versions of Ozempic Hit Sales
Trending Stocks Today | NetClass Technology Shoots up 42.45% Pre-Market
Novo Nordisk Q1 Earnings, Sales Rise; 2025 Outlook Lowered
Why Porch Group Shares Are Trading Higher By Over 21%; Here Are 20 Stocks Moving Premarket
Stocks to Watch Wednesday: Disney, Uber, Super Micro -- WSJ
The blockbuster weight loss drug is under attack from knockoffs, while Novo-Nordisk A/S's profits are surprising but fail to conceal underlying concerns.
① Novo-Nordisk A/S's net income for the first quarter of 2025 was 29.034 billion Danish krone, a year-on-year increase of 14%, exceeding Analyst predictions; ② Novo-Nordisk A/S has lowered its full-year sales growth forecast to 13%-21%, attributing this to competitive pressures from compound pharmaceuticals in the USA market. Additionally, the company also faces challenges from Other pharmaceutical giants.
Jeffy Invests : $Hims & Hers Health (HIMS.US)$
